 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast...

Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award

Theratechnologies (NASDAQ:THTX  Get Free Report) and Moleculin Biotech (NASDAQ:MBRX  Get Free Report) are both small-cap medical companies, but which is the superior business? We will...

Theratechnologies (NASDAQ:THTX) and Moleculin Biotech (NASDAQ:MBRX) Financial Comparison

This news release constitutes a designated news release for the purposes of the Company's prospectus supplement datedDecember 16, 2021 to its short form base shelf prospectus dated December 14...

Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement

This news release constitutes a designated news release for the purposes of the Company's prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14...

Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Theratechnologies announces common stock offering, private placement

Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement

Theratechnologies Announces Operational Update

Theratechnologies' Ibalizumab demonstrates cost-effectiveness

Data presented at AMCP Nexus 2023 highlight implications for U.S. payers based on cost-effectiveness and improved outcomes This news release constitutes a designated news release for the purposes...

Theratechnologies' Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV

- Revised the Minimum Liquidity Covenant for All Times Following October 31, 2023 to be Between US$15 Million and US$20 Million - Minimum Quarterly Revenue Covenant Replaced with Minimum...

Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montréal, Canada.

Watchers	1,090
52-Wk Low	$0.88
52-Wk High	$5.96

Market Cap	$54.45M
Volume (M)	30.00
52-Wk High	$5.96
52-Wk Low	$0.88

THTX Theratechnologies Inc.

About

Feed

News

Earnings

Fundamentals